A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

M
Michael Robertson, MD

Primary Investigator

Overview

The purpose of this study is to compare overall survival in MCL patients in MRD-negative first complete remission (CR) who undergo auto-HCT followed by maintenance rituximab vs. maintenance rituximab alone (without auto-HCT).

Description

The purpose of this study is to compare overall survival in MCL patients in MRD-negative first complete remission (CR) who undergo auto-HCT followed by maintenance rituximab vs. maintenance rituximab alone (without auto-HCT).

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Mantle Cell Lymphoma
  • Age: - 100 Years
  • Gender: All

Inclusion Criteria

Patients must have histologically confirmed mantle cell lymphoma, with documented cluster of differentiation (CD19) or CD20 expression and cyclin D1 (BCL1) by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ hybridization (FISH); the diagnosis must be confirmed by formal hematopathology review at the enrolling center, including assessment of Ki-67 proliferation index (=< 30% versus > 30% versus ?indeterminate? Ki-67 index)

Patients should be deemed to be potentially eligible and willing candidates for auto-HCT by the enrolling physician

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 20 Nov 2022. Study ID: 1804274223 (EA4151/BMTCTN1601)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center